Asciminib, an inhibitor specifically targeting the ABL myristoyl pocket (STAMP) (Wylie et al. 2017; Manley et al. 2020; Novartis 2021), is promising for use as a targeted agent in patients with CP-CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.